Posted by Michael Wonder on 01 Dec 2021
Zogenix announces U.S. FDA acceptance for priority review of supplemental new drug application for Fintepla (fenfluramine) for the treatment of seizures associated with Lennox-Gastaut syndrome
1 December 2021 - Prescription Drug User Fee Act target action date of 25 March 2022.
Zogenix today announced the U.S. FDA has accepted for filing and granted priority review to the company’s supplemental new drug application for the use of Fintepla for the treatment of seizures associated with Lennox-Gastaut syndrome.
